<?xml version="1.0" encoding="UTF-8"?>
<p>Brincidofovir, the lipid-conjugate of the nucleotide analog Cidofovir, can achieve over 100-fold higher intracellular levels compared with Cidofovir (see 
 <xref ref-type="fig" rid="fig2">Figure 2(b)</xref>). The low plasma levels promote less toxicity, and nephrotoxicity is avoided as there is no binding to anion transporters in the kidney [
 <xref rid="B8" ref-type="bibr">8</xref>, 
 <xref rid="B11" ref-type="bibr">11</xref>]. BCV has a twice weekly oral dosing, low toxicity, and broad spectrum antiviral activity, including CMV, EBV, acyclovir-resistant HSV, and BK-virus, even without immune reconstitution [
 <xref rid="B11" ref-type="bibr">11</xref>].
</p>
